In the latest market close, Medpace (MEDP) reached $443, with a +1.84% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Meanwhile, the Dow experienced a rise of 0.62%, and the technology-dominated Nasdaq saw an increase of 0.63%. Coming into today, shares of the provider of outsourced clinical development services had gained 10.38% in the past month. In that same time, the Medical sector gained 0.19%, while the S&P 500 gained 4.28%. Market ...

Medpace (MEDP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The Zack ...

Have you been paying attention to shares of Medpace (MEDP) ? Shares have been on the move with the stock up 10% over the past month. The stock hit a new 52-week high of $424.49 in the previous session. Medpace has gained 38.4% since the start of the year compared to the 5.9% move for the Zacks Medical sector and the 5.4% return for the Zacks Medical Services industry. For the current fiscal year, Medpace is expected to post earnings of $11.28 per share on $2.17 billion in revenues. This represents a 27.14% ...

The most recent trading session ended with Medpace (MEDP) standing at $405.33, reflecting a -0.53% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.16%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.49%. The investment community will be closely monitoring the performance of Medpace in its forthcoming earnings report. The company is forecasted to report an EPS of $2.52, showcasing a 30.57% upward movement from the corresponding quarter of t ...

The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is expected to report EPS of $2.52, up 30.57% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $529.73 million, up 14.94% from the year-ago period. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Z ...

Investors will be eagerly watching for the performance of Medpace in its upcoming earnings disclosure. In that report, analysts expect Medpace to post earnings of $2.52 per share. This would mark year-over-year growth of 30.57%. Our most recent consensus estimate is calling for quarterly revenue of $529.73 million, up 14.94% from the year-ago period. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by ex ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss. However, it's pretty easy to find cutting-edge ...

In the latest market close, Medpace (MEDP) reached $390.81, with a +0.07% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.03%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq gained 0.59%. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Medpace (MEDP) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Medpace is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different groups, measuring the ...